Technical Chemicals and Products, Inc.
This article was originally published in The Gray Sheet
Firm will relocate its Pharmetrix division and close its transdermal R&D facility in Menlo Park, California upon expiration of the lease next month as part of an ongoing program to increase operating efficiency, the company announces May 19. The move comes one week after retaining Janssen/Meyers Associates, LP for investment banking services and consulting on corporate finance and strategic transactions. TCPI will maintain associated patents and continue development of its transdermal drug delivery and skin permeation technologies at corporate headquarters in Pompano Beach, Florida. The firm says it is currently discussing development of the Pharmetrix product and patent portfolios with several pharmaceutical companies
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.